KRAS and lung carcinoma: Interestingly, TMEM106B gain or amplification status in human nonsmall cell lung cancer (NSCLC) patients is not significantly associated with the KRAS mutational status, indicating that TMEM106B is an independent prognostic driver of lung cancer metastasis (Supplementary Figure 5G).